Proactive Investors - Run By Investors For Investors

Aequus Pharmaceuticals establishes advisory board in ophthalmology

They are Dr Ike Ahmed who will become chairman and Dr Rosa Braga-Mele, who comes from the University of Toronto.
Aequus Pharmaceuticals establishes advisory board in ophthalmology
The company has established an advisory board

Aequus Pharmaceuticals Inc (CVE:AQS) told investors it had established a strategic advisory board in ophthalmology and appointed its first two members.

They are Dr Ike Ahmed of the Prism Eye Institute, who will become chairman and Dr Rosa Braga-Mele, who comes from the University of Toronto.

This board will help Aequus in determining whether a product can improve patient outcomes, integrate into a clinician's workflow, and navigate the Canadian reimbursement and commercial landscape.

"The formation of our advisory board is another step in our continued commitment to the ophthalmic space in Canada," said Doug Janzen, chairman and CEO of Aequus Pharmaceuticals.

Dr Ahmed has become world renowned for his skills and ground-breaking work in the diagnosis and surgical treatment of highly complex eye diseases including glaucoma and surgical complications

Dr Rosa Braga-Mele is a cataract specialist and educator who speaks frequently at both the national and international level on advanced surgical techniques, innovations in phacoemulsification surgery, complicated cataract cases, and IOL development.

View full AQS profile View Profile

Aequus Pharmaceuticals Inc Timeline

Related Articles

1537236236_main-better-use.jpg
September 17 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
Cancer cells
February 06 2019
In October 2018, Maxcyte saw the first patient dosed in an initial phase I trial using its lead MCY-M11 therapy, tracking a total of 15 women with relapsed or hard-to-treat forms of cancer
researcher at microscope
May 24 2019
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use